Evotec SE (EVT) - Total Liabilities
Based on the latest financial reports, Evotec SE (EVT) has total liabilities worth €940.19 Million EUR (≈ $1.10 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evotec SE - Total Liabilities Trend (2003–2025)
This chart illustrates how Evotec SE's total liabilities have evolved over time, based on quarterly financial data. See EVT working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Evotec SE Competitors by Total Liabilities
The table below lists competitors of Evotec SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sats ASA
OL:SATS
|
Norway | Nkr8.18 Billion |
|
Anhui Coreach Technology Co Ltd
SHE:002983
|
China | CN¥563.08 Million |
|
Sichuan Shudao Equipment & Technology Co Ltd
SHE:300540
|
China | CN¥966.60 Million |
|
Beijing Navigation Control Technology Co. Ltd.
SHG:688282
|
China | CN¥227.23 Million |
|
Drägerwerk AG & Co. KGaA (pref)
F:DRW3
|
Germany | €1.51 Billion |
|
Chipsea Technologies Shenzhen Corp Ltd
SHG:688595
|
China | CN¥748.77 Million |
|
ODP Corp
NASDAQ:ODP
|
USA | $2.46 Billion |
|
Welspun Enterprises Limited
NSE:WELENT
|
India | Rs35.17 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Evotec SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVT market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evotec SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evotec SE (2003–2025)
The table below shows the annual total liabilities of Evotec SE from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €965.05 Million ≈ $1.13 Billion |
+0.53% |
| 2024-12-31 | €959.98 Million ≈ $1.12 Billion |
-15.24% |
| 2023-12-31 | €1.13 Billion ≈ $1.32 Billion |
+5.84% |
| 2022-12-31 | €1.07 Billion ≈ $1.25 Billion |
+24.79% |
| 2021-12-31 | €857.48 Million ≈ $1.00 Billion |
+16.21% |
| 2020-12-31 | €737.88 Million ≈ $862.66 Million |
+4.83% |
| 2019-12-31 | €703.88 Million ≈ $822.91 Million |
+102.85% |
| 2018-12-31 | €347.00 Million ≈ $405.68 Million |
+3.42% |
| 2017-12-31 | €335.52 Million ≈ $392.26 Million |
+144.14% |
| 2016-12-31 | €137.43 Million ≈ $160.67 Million |
+35.47% |
| 2015-12-31 | €101.44 Million ≈ $118.60 Million |
+53.20% |
| 2014-12-31 | €66.22 Million ≈ $77.41 Million |
-3.21% |
| 2013-12-31 | €68.41 Million ≈ $79.98 Million |
-6.13% |
| 2012-12-31 | €72.88 Million ≈ $85.20 Million |
+2.69% |
| 2011-12-31 | €70.97 Million ≈ $82.97 Million |
+19.83% |
| 2010-12-31 | €59.22 Million ≈ $69.24 Million |
+68.67% |
| 2009-12-31 | €35.11 Million ≈ $41.05 Million |
+6.27% |
| 2008-12-31 | €33.04 Million ≈ $38.63 Million |
-11.48% |
| 2007-12-31 | €37.33 Million ≈ $43.64 Million |
-45.39% |
| 2006-12-31 | €68.35 Million ≈ $79.91 Million |
+82.55% |
| 2005-12-31 | €37.44 Million ≈ $43.77 Million |
+307.75% |
| 2004-12-31 | €9.18 Million ≈ $10.74 Million |
+61.18% |
| 2003-12-31 | €5.70 Million ≈ $6.66 Million |
-- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more